STOCK TITAN

Theriva Biologics Inc - TOVX STOCK NEWS

Welcome to our dedicated news page for Theriva Biologics (Ticker: TOVX), a resource for investors and traders seeking the latest updates and insights on Theriva Biologics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Theriva Biologics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Theriva Biologics's position in the market.

Rhea-AI Summary
Theriva Biologics announced that the independent data monitoring committee recommended the continuation of enrollment into VIRAGE, a Phase 2b clinical trial evaluating VCN-01 in combination with standard-of-care chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma. The IDMC's assessment found no safety concerns, and VIRAGE remains on track to complete enrollment in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.58%
Tags
clinical trial
-
Rhea-AI Summary
Theriva Biologics, Inc. (TOVX) will participate in a fireside chat at the B. Riley Securities Oncology Conference on January 18, 2024. The company is a clinical-stage developer of therapeutics for cancer and related diseases. The event will be held virtually at 9:30 a.m. ET, and the presentation replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
TOVX - Theriva Biologics Reports Positive Clinical Data and Financial Results, Expects to Complete Enrollment for VIRAGE Trial in 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.38%
Tags
earnings
Rhea-AI Summary
Theriva Biologics (TOVX) will host a conference call on November 13, 2023, to discuss its financial results for Q3 2023 and provide a corporate update. Investors can participate via telephone or access the webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.64%
Tags
conferences earnings
-
Rhea-AI Summary
Theriva Biologics will provide a corporate update and participate in one-on-one meetings at the BIO-Europe Conference in Munich from November 6-8, 2023. The presentation is scheduled for Tuesday, November 7, 2023, at 11:15am CET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
conferences
-
Rhea-AI Summary
Theriva has signed an exclusive option to license intellectual property from Sant Joan de Déu-Barcelona Children’s Hospital (SJD) to explore the therapeutic potential of VCN-01 in combination with topoisomerase I inhibitors. The collaboration strengthens the long-term research partnership between Theriva and SJD and builds on an ongoing trial evaluating VCN-01 in pediatric cancers. The combination of VCN-01 with topoisomerase I inhibitors has shown a synergistic antitumor effect in preclinical cancer models. Theriva will pay SJD an option fee of €25,000.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Theriva Biologics announces new clinical data from Phase 1 study of VCN-01 in combination with durvalumab for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). Results show enhanced patient survival and upregulation of PD-L1, correlating with increased CPS score. Webinar featuring expert oncologist Ricard Mesia M.D., Ph.D. to be held today.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
clinical trial
-
Rhea-AI Summary
Theriva Biologics (TOVX) to provide corporate update and participate in investor meetings at Emerging Growth Conference on Oct 5. Webcast available through conference portal and YouTube Channel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences acquisition
-
Rhea-AI Summary
Theriva Biologics has initiated dosing at U.S. sites for VIRAGE, a Phase 2b clinical trial of VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma. The trial is expected to complete enrollment in Q1 2024. VCN-01 has been granted Orphan Drug Designation by the U.S. FDA for the treatment of pancreatic cancer. Ramon Alemany, Ph.D., has been appointed as Senior Vice President of Discovery. As of June 30, 2023, Theriva Biologics reports $34.2 million in cash, providing runway into Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
earnings
Rhea-AI Summary
Theriva Biologics, a clinical-stage company, has initiated dosing at U.S. sites for VIRAGE, a Phase 2b clinical trial evaluating VCN-01 in combination with standard-of-care chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma. The trial remains on track to be fully enrolled in the first quarter of 2024. Dosing in Spain has also been initiated and the first patients have received their second doses of intravenous VCN-01, which were well tolerated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.15%
Tags
clinical trial
Theriva Biologics Inc

NYSE:TOVX

TOVX Rankings

TOVX Stock Data

8.01M
16.71M
1.94%
5.94%
2.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Rockville

About TOVX

synthetic biologics, inc. (nyse mkt: syn) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. the company's lead candidates poised for phase 3 development are: (1) syn-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (ibs-c), and (2) syn-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (iv) beta-lactam antibiotics for the prevention of c. difficile infection (cdi), antibiotic-associated diarrhea (aad) and the emergence of antimicrobial-resistance (amr). the company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (pku).